<span item_type="fundamental" item_id="89eeec0df7ed6d45942d95ec07f5b50b" counter_id="ST/US/NMRA" env="prod"></span><span item_type="announcement" item_id="579761624824354305" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.35, missing the estimate of USD -0.3334.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -58.64 M.</p><p></p><h3>Financial Metrics Summary</h3><h4>Cash Position</h4><ul><li>As of September 30, 2025, Neumora Therapeutics had cash, cash equivalents, and marketable securities totaling $171.5 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm"></span></li></ul><h4>Research and Development (R&amp;D) Expenses</h4><ul><li>R&amp;D expenses for the third quarter of 2025 were $40.5 million, a decrease from $60.6 million in the same period of 2024. This reduction was primarily due to the expiration of research and collaboration agreements with Amgen and a decrease in clinical trial costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm"></span></li></ul><h4>General and Administrative (G&amp;A) Expenses</h4><ul><li>G&amp;A expenses for the third quarter of 2025 were $12.2 million, down from $16.0 million in the same period of 2024, mainly due to lower consulting and personnel-related costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>The net loss for the third quarter of 2025 was $56.8 million, compared to a net loss of $72.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm"></span></li></ul><h4>Financial Guidance</h4><ul><li>The company expects its cash, cash equivalents, and marketable securities as of September 30, 2025, to fund its operating plan into 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Neumora plans to initiate a clinical program with NMRA-215 in the first quarter of 2026, with human proof of concept data expected later that year. The company is also on track to report data from a Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around the end of 2025. Additionally, topline data from the Phase 3 KOASTAL program for navacaprant in major depressive disorder is expected in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-ex99_1.htm"></span></li></ul>

Neumora Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0